Is Regeneron (REGN) Still Attractively Priced After Mixed Recent Share Performance [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Wondering if Regeneron Pharmaceuticals at around US$764.93 a share still offers value, or if most of the upside is already priced in? This article is designed to help you frame that question clearly. The stock has seen mixed recent returns, with a 0.8% gain over the last 30 days, a 1.5% decline year to date, and a 10.1% return over the past year. These figures can hint at shifting views on both growth potential and risk. Recent news around Regeneron Pharmaceuticals has focused on its position within the broader pharmaceuticals and biotech space, along with investor interest in how its drug portfolio and pipeline support the current share price. These updates are important context when you think about whether the recent 3.5% three year and 63.9% five year returns align with what the company is fundamentally worth today. On Simply Wall St's valuation checks, Regeneron Pharmaceuticals currently scores 5 out of 6 . This suggests several metrics screen as undervalued and sets us up
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.MarketBeat
- Dupixent Approvals Expand Regeneron's Immunology Reach And Valuation Debate [Yahoo! Finance]Yahoo! Finance
- Regeneron Announces Investor Conference Presentation [Yahoo! Finance]Yahoo! Finance
- Regeneron Announces Investor Conference PresentationGlobeNewswire
- 2 Biotech Giants to Buy in 2026 [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website